Nasdaq Biotech (HILS) Is A Tiny Float Breakout Idea Riding Game-Changing Agreement News This Week
Let's move quickly this morning.
Right now, I'm bringing you a new Nasdaq breakout idea.
Why is this one special? I'll tell you.
According to Cary Gross, the director of the National Clinical Scholars Program at Yale, "The U.S. is spending over $200Bn per year on cancer care—roughly $600 per person, in comparison to the average of $300 per person across other high-income countries."(1)
That's a lot of scratch. It's also why I like to keep an eye on biotechnology companies.
One company in particular is flying under Wall Street's radar right now, but I'm not sure for how much longer.
With the company advancing multiple cancer therapeutic candidates in their pipeline, it may be just a matter of time until they go from "little known" to "well known" if you get what I'm saying.
But before they receive a broader audience, I want you to get them on your radar.
Plus, factor in that Yahoo Finance is reporting a float of fewer than 4Mn shares and the company having game-changing news this week, and you'll see why they need top spot on your radar immediately.
Drop everything and get this Nasdaq breakout idea on your screen:
*Hillstream BioPharma, Inc. (HILS)*
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death ("IMCD") for drug resistant and devastating cancers. Our most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors.
And right now, HILS has 4 key potential catalysts to soak in. Check them out:
No. 1 - A Low Float Could Provide The Recipe For Extreme Volatility
No. 2 - Tuesday's Huge News Creates Quite The Buzz (Game-Changing Agreement)
No. 3 - Company Enters Rapidly Growing Immuno-oncology Market Through Key Collaboration
No. 4 - Key Lines Of Potential Support Could Become Building Blocks For Return To Previous Highs
But more on those in a second...
February 2023 Official Profile: Hillstream BioPharma, Inc. (HILS)
Hillstream Biopharma is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers.
Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors.
Hillstream uses Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity.
In addition, Trident Artificial Intelligence (TAI), Hillstream’s artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target a specific patient segment most likely to benefit.
Quatramer is tumor-targeted platform with capacity to deliver drug and biologic combinations
Quatramer is a tumor targeting platform which allows us to leverage and exploit key tumor targets and novel emerging pathways such as IMCD to facilitate the delivery of potent drugs directly to the TME, while sparing healthy tissue. By efficiently extending the circulation half-life, as well as targeting delivery to the tumor site, Quatramer traps drugs into the TME. This emerging orthogonal anti-cancer approach utilizes a fundamental recognized mechanism of iron mediated tumor growth and metabolism. We are building a portfolio of long-acting, potent anti-cancer drug candidates using our Quatramer platform.
Quatramer based compounds with therapeutic cargoes from our product pipeline include DNA-based contents which hijack the tumor’s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as TNF-alpha and potentially others. The platform’s tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses in order to eradicate rare cancers and treatment resistant tumors with minimal or no treatment options.
Trident is a Deep Learning Engine that identifies synthetic lethal sensitivities associated with degree of cell plasticity
Trident, as the name suggests, takes a multi-pronged approach to address each of the leading causes of tumor plasticity as the disease progresses namely Epithelial-to-mesenchymal transition, Dedifferentiation/Transdifferentiation, and Transient drug-induced tolerance and sensitivity. The platform builds on a deep foundation of diverse multi-modal and multi-omic private and public datasets which include not only genomic and transcriptomic data from patient derived blood or biopsy samples and sublines, and pan-cancer epigenetic and transcriptional drug response data from The Cancer Genome Atlas (TCGA), Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC), but also human cancer proteome datasets from emerging global efforts that include Human Cancer Proteome Project (HUPO; Cancer-HPP), The Cancer Proteome Atlas (TCPA) and The National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC). Inclusion of proteomics data is very critical for identifying dynamical re-wiring of intra-tumoral signaling circuitry which is likely to be missed if one looks at the genomic and transcriptomic level alone.
Trident is a Deep Learning Engine that integrates in vitro and in vivo epigenetic, transcriptomic and proteomic data characterizing genomic alterations, methylation states, cellular differentiation, and drug tolerance to identify:
Biomarker fingerprints that deconvolve a heterogeneous tumor biopsy into a discrete phenotypic state along a gradient of progressive cellular plasticity, Network of dis-regulated functional pathways that underscore a patient’s pathology, and Indication-specific synthetic-lethal sensitivities to drugs
Trident utilizes state-of-the-art convolutional neural networks to classify and select patients based on their tumor-derived multi-comic profiles thus enabling a targeted synthetic-lethal approach to kill persistent tumor cell populations and treat patients in select indications.
Trident maps the phenotypic tumor transition from a high-dimensional landscape onto a quantitative, measurable one-dimensional scale
Trident traces the complex high-dimensional landscape of tumor progression to identify biomarkers that mark milestones in this continuum and enable quantification of degree of plasticity along the trajectory. Trident’s Deep Learning Engine trains a model that can reduce this high-dimensional information into a one-dimensional quantitative and measurable scale which informs what is the degree of plasticity in a biopsy sample or cell line dataset. Trident’s unbiased search in the vast repository of multi-modal datasets enables identification of synthetic lethal sensitivities that correlate linearly but contrast with degree of plasticity. This biomarker-guided, state-specific approach enables to successfully deconvolve signals from a heterogenous tumor biopsy into a discrete phenotypic state along a gradient of progressive and divergent cellular plasticity and complementary synthetic lethal sensitivity.
Trident is designed to de-risk clinical development and deliver on the promise of precision medicine
Trident is designed to deliver on Hillstream Bio’s ultimate goal, which is to identify and treat the right patients that are most likely to benefit from treatment. Using Trident, biomarkers measured in patient blood/biopsy samples will assist in determining the degree of plasticity for a specific patient, which will then directly inform about a patient’s sensitivity to activation/inhibition of the synthetically lethal target and probability of successful treatment. More than just de-risking clinical development, Trident aspires to deliver on the promise of precision medicine by building a platform based on the robust foundation of patient-based biomarker research and deep learning artificial intelligence technologies.
The Hillstream Biopharma Pipeline